Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Moderna Inc’s stock clocked out at $44.94, up 7.90% from its previous closing price of $41.65. In other words, the price has increased by $7.90 from its previous closing price. On the day, 13.24 million shares were traded. MRNA stock price reached its highest trading level at $45.15 during the session, while it also had its lowest trading level at $40.75.
Ratios:
To gain a deeper understanding of MRNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.20 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
On November 19, 2024, Berenberg started tracking the stock assigning a Hold rating and target price of $42.Berenberg initiated its Hold rating on November 19, 2024, with a $42 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 09 ’24 when Klinger Shannon Thyme sold 529 shares for $44.68 per share. The transaction valued at 23,637 led to the insider holds 20,446 shares of the business.
Klinger Shannon Thyme bought 529 shares of MRNA for $23,637 on Dec 09 ’24. On Dec 03 ’24, another insider, Klinger Shannon Thyme, who serves as the Chief Legal Officer of the company, sold 112 shares for $43.30 each. As a result, the insider received 4,849 and left with 19,837 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 17293719552 and an Enterprise Value of 11781712896. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.41 while its Price-to-Book (P/B) ratio in mrq is 1.45. Its current Enterprise Value per Revenue stands at 2.319 whereas that against EBITDA is -4.988.
Stock Price History:
The Beta on a monthly basis for MRNA is 1.59, which has changed by -0.5878278 over the last 52 weeks, in comparison to a change of 0.25219524 over the same period for the S&P500. Over the past 52 weeks, MRNA has reached a high of $170.47, while it has fallen to a 52-week low of $31.94. The 50-Day Moving Average of the stock is 10.55%, while the 200-Day Moving Average is calculated to be -46.32%.
Shares Statistics:
It appears that MRNA traded 9.88M shares on average per day over the past three months and 14346850 shares per day over the past ten days. A total of 385.00M shares are outstanding, with a floating share count of 343.19M. Insiders hold about 10.82% of the company’s shares, while institutions hold 67.48% stake in the company. Shares short for MRNA as of 1736899200 were 43006951 with a Short Ratio of 4.35, compared to 1734048000 on 39488336. Therefore, it implies a Short% of Shares Outstanding of 43006951 and a Short% of Float of 14.7.
